Ocugen Achieves Key Milestones in Advancing Gene Therapy Programs for Geographic Atrophy and Retinitis Pigmentosa’
MALVERN, Pa. May 31, 2024 - Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a forefront contender in biotechnology dedicated to pioneering novel gene and cell therapies alongside vaccines, has recently made significant progress in its clinical development initiatives. The advancements span two promising gene therapy products’OCU410 and OCU400’targeting debilitating eye diseases: geographic atrophy (GA) and retinitis pigmentosa (RP), respectively.
Ocugen has ventured into new territory with its cutting-edge OCU410 (AAV5-hRORA), a modifier gene therapy candidate poised to address GA, an advanced stage of dry age-related macular degeneration (dAMD). GA afflicts an estimated 2-3 million individuals across the U.S. and Europe, making it a critical area of focus. The recent Data and Safety Monitoring Board (DSMB) review for Ocugen’s Phase 1/2 ArMaDa clinical trial heralds a positive outcome, permitting the simultaneous enrollment of patients in Cohort 3 and the initiation of Phase 2 of the study. This advancement signifies a pivotal moment in the clinical trajectory of OCU410.
Prior to this landmark approval, Ocugen had announced on April 19, 2024, the successful completion of dosing for subjects enrolled in the second cohort of the same Phase 1/2 ArMaDa clinical trial. This milestone reinforces the robust data collection efforts and patient safety monitoring that paved the way for the trial’s progression to Cohort 3 and Phase 2. This meticulous approach underscores Ocugen’s commitment to advancing OCU410 as a potential therapeutic intervention for GA, impacting approximately 1 million individuals in the United States alone.
Parallel to its achievements with OCU410, Ocugen has also made headway with OCU400, another promising modifier gene therapy candidate targeting broad-spectrum retinitis pigmentosa (RP). On April 10, 2024, the company announced that it had received positive scientific advice from the European Medicines Agency (EMA). The Committee for Medicinal Products for Human Use (CHMP) reviewed and endorsed the study design, endpoints, and planned statistical analysis for the pivotal Phase 3 liMeliGhT clinical trial based in the U.S. This endorsement not only validates Ocugen’s clinical approach but also aligns the study outcomes with the criteria required for the submission of a Marketing Authorization Application (MAA) in the European Union.
The confluence of these developments marks an epoch in Ocugen’s mission to deliver transformative gene therapies. The dual progress of OCU410 and OCU400 not only embodies substantive clinical and regulatory success but also heralds a potential future where advanced gene therapies can remediate severe ocular conditions, enhancing the quality of life for millions affected by GA and RP.
Ocugen’s relentless pursuit of innovation and patient-centric clinical development continues to propel the company towards frontline therapeutic solutions, aiming for breakthroughs that could revolutionize the landscape of gene therapy in ophthalmology.
Comments